A Phase 1 Study of EBC-129 in Advanced Solid Tumours
Status:
Not yet recruiting
Trial end date:
2025-05-04
Target enrollment:
Participant gender:
Summary
This study will assess the safety and tolerability of EBC-129 as a single agent and in
combination with pembrolizumab in patients with advanced solid tumours
Phase:
Phase 1
Details
Lead Sponsor:
EDDC (Experimental Drug Development Centre), A*STAR Research Entities